Company intelligence / Profile preview

MitoKor

San Diego, California, United Statesbloomberg.com ↗

Ownership: Private
Employees: ~25
Development stage: Phase 2

Overview

MitoKor developed multiple preclinical and clinical candidates addressing mitochondrial dysfunction in neurological and degenerative diseases. As of the 2004 Micrologix acquisition, there were two candidates entering Phase III, three in Phase I/II, and seven preclinical programs including in Alzheimer's, arthritis, and Parkinson's disease. All original development as MitoKor has been discontinued under the acquiring company[1][3][4].

Therapeutic areas: Metabolic DisordersOncologyNeurology
Modalities: Small moleculeBiologic
Industry: Biotech

Partnerships

PfizerWyeth

Beyond the preview

Go deeper on MitoKor.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MitoKor.

Explore the full profile